Nuinerous studies have indicated a role of epidermal growth factor in the maintenance of the gastrointestinal mucosa.
Introduction
,. , , , ., , ,, . . and sahvary glands, the parotid gland being the major Epidermal growth factor is a single^chain polypeptide source of synthesis and secretion (4) . of M r 6000 consisting of 53 amino acids (l, 2). Epi- 1 6 role of epidermal growth factor in the pathogendermal growth factor produces a varfety of biological esis O f gastrointestinal ulcer disease has received much responses including euhanced proliferation and dif-attention in the past few years. The "rediscovery" of ferentiation of epithelial tissues in vivo and in vitro. Campylobacter pylori demonstrates that the "ulcer Numerous target structures and different modes of discussion" is still controversial (5) . The purpose of action reveal similarities between epidermal growth the ^ study is the further elucidation of the factor and polypeptide hprmones such äs insulin (3) . possible involvement of epidermal growth factor in Epidermal growth factor has been detected in almost ulcer disease -all body fluids, whef eas synthesis in man has so far High concentrations of epidermal growth factor have only been shown in Brunner glands of the duodenum been known for a long time to inhibit gastric secretion 540 Hansen et al.: Epidcrmal growth factor in gastrointestinal ulcer (6) . Apart from this artificial effect, many fmdings suggest that it participates in the maintenance of the gastrointestinal mucosa (7, 8) . These studies, however, are based on animal models. The earliest data on the concentration of epidermal growth factor in the saliva of patients with gastrointestinal ulcer, compared with healthy controls, were reported by Ohmura et al. (9) . As these results could not be confirmed in our investigations, definite evidence is still lacking that epidermal growth factor in human gastrointestinal ulcer disease is subject to any alteration.
The present study was performed in order to examine epidermal growth factor concentrations in saliva and gastric juice of patients with gastrointestinal complaints (gastric ulcer, duodenal ulcer, gastritis) and healthy controls. The use of a sensitive, specific and practicable assay System for routine measurement is a prerequisite, in order to establish the pathophysiological role or even clinical relevance of epidermal growth factor in various body fluids. In this paper we present the development of a novel ELISA for human epidermal growth factor, which involves some unusual processing stages. This assay is less time-consuming than any comparable assay published, and it meets all requirements mentioned above.
Materials and Methods

Reagents
Goat-IgG F(ab') 2 : anti mouse-IgF (Fc) was obtained from Jackson, Dianova, Hamburg, FRG; human epidermal growth factor (human urine), rabbit anti mouse-epidermal growth facton streptavidin-peroxidase 1 ) from Calbiochem, Frankfurt, FRG; rabbit serum from Gibco, Karlsruhe, FRG; NHS-LCbiotin (N[6-(biotinamido)hexanoyloxy]sulphosuccinimide) from Pierce, Oud Beijerland, Netherlands; 3,3',5,5'-tetramethylbenzidine (TMB) from Fluka, Buchs, Switzerland; mouse monoclonal anti human-epidermal growth factor antibodies from AMGEN, Thousand Oaks, California, USA.
Rabbit anti human-epidermal growth factor antiserum was kindly provided by Dr. H. Gregory, ICI, Macclesfield, UK.
was used before sample withdrawal. The endoscopies were performed for sound medical reasons and not for the purpose of the present investigation.
Total 15 minutes Output could be measured by aspiration, using gastric tubes (UNO) that were placed in the antrum under Xray control.
Epidermal growth factor concentration was measured in gastric juice of patients with acute gastric ulcers (n = 9), gastric ulcers under treatment (2 40 mg/d famotiäin) (n = 9), duodenal ulcers (n = 14), gastritis (n = 22) and healthy controls (n = 19).
The 15-minute^output of epidermal growth factor was determined in the gastric juice of patients with treated gastric ulcer (n = 8), duodenal ulcer (n = 6), gastritis (n = 7) and healthy controls (n = 14). Saliva (2-3 ml) was collected without Stimulation before endoscopic examination from patients with gastrie ulcer (treated and untreated) (n = 11), patients with duodenal ulcer (n = 4), and patients with gastritis (n = 10). Total saliva secretion in deflned periods could not be ascertained due to the disturbance and Interruption of routine endoscopy. Saliva samples and 15-minute gastric juice volumes were collected from the same patients who underwent sample collection during endoscopic examination. Patients with acute gastric ulcer and with ulcer under treatment were different individuals. For saliva examination gastric ulcer patient groups were not sepairated intq acute and treated gastric ulcer.
All diagnoses were confirmed by endoscopy and histology. In the case of patients with treated ulcers, samples were collected during control endoscopy or after control endoscopy (for output-determination), respectively.
All samples were centrifuged at 15000g for 5 minutes and stored at -40 °C untü use.
Biotinylated immunoglobulins
Immunoglobulin fractions were prepared from whole antisera by repeated ammonium sulphate precipitation at 0.40 Saturation. After redissolving the pellet in distilled water, the sample was desalted by chromatography on Sephadex G-25 fine, equilibrated with 0.015 mol/1 södium phosphate, pH 7.4. The protein concentration of the eluate was determined according to Bradford (10 Epidermal growth factor-ELISA Microtitre-plates were coated by adding 150 of a 1:250 dilution (v/v) goat-F(ab')2 anti mouse-IgG (Fc) in 0.015 mol/i phosphate buffer, pH 7.4. After 2 hours, the microtitre plates were washed 3 with wash buffer (0.015 mol/l phosphate buffer, pH 7.4 containing l g/l fween 20) and l with distilled water, vacuum-dried and stored desiccated at 4 °C for up to 6 months. Standards at 0.05, 0.1, 0.2, 0.5, l and 2 ^/1 in assay buffer .(10 ml/l rabbit serum in wash buffer) were prepared daily from a 10 mg/1 stock human epidermal growth factor solution in ethylene glycol volume fraction 0.50 stored in aliquote at -20 °C.
Serum samples were used undiluted; saliva ät ä l: 2 dilution, urines at a l: 50 and a l: 500 (v/v) dilution in assay buffer; gastric juice at a 1:2 (v/v) dilution in 0.15 inöl/1 phosphate buffer, pH 7.4 (which adjusts the pH of the gastric juice to above 7.0).
541
For the assay, 60 μΐ of Standard or sample were placed in duplicate into consecutive wells of a coated microtitre plate. An 8 h incubation period at room temperature was started by adding 90 μΐ of an antibody mixture containing the monoclonal anti epidermal growth factor at a l: 90 000 dilution and the biotinylated rabbit anti epidermal growth factor at a l: 9000 dilution in assay buffer.
After 2 washes, 150 μΐ streptavidin-peroxidase at a 1:5000 dilution in assay bufter were added for 30 min.
After 6 washes, 150 μΐ tetramethylbenzidine Substrate solution in pH 3.95 citrate/H 2 O 2 buffer (11) were added and left for 10 min. The reaction was stopped by addition of 50 μΐ 2 mol/1 sulphuric acid and the absorbance read at 450 and 492 nm (measuring and reference wavelength, respectively).
The test scheme is illustrated in figure l.
Statistical analysis
Statistical differences were evaluated by the U-test according to Wilcoxon, Mann & Whitney (12) .
Results
Our new ELISA procedure yields a linear Standard curve with epidermal growth factor concentrations up to 2 μ §/1 ( fig. 2 ). The lower detection limit of epidermal growth factor in body fluids can be considered to be approximately 20 ng/1 (determined by calculating the mean ± 3 SD of 8 replicate measurements of the zero sample). Within the measuring r nge (0.02-2 μg/l) the maximal intra-and interassay imprecision was 5% and 9%, respectively.
As an indication of test linearity, the dilution curves of different sample materials are demonstrated in figure 3 . The coefficient of correlation (r) of the dilutions l: 32 to l: 2 with their measured concentrations is 0.97.
When defined amounts of epidermal growth factor were added to different sample material, the recovery was 92%-103% (tab. 1).
No sex or age-dependent differences in epidermal growth factor concentration were noticed in saliva or gastric juice of healthy controls.
Four healthy volunteers endured our "thirst-experiments" in which 5-minute-saliva-samples were collected at 08.00 AM after 12 hours thirst/fasting period. After another 4 hours period a second 5-minutesaliva-sample was obtained. Thirty minutes after water Substitution (0.71 mineral water following a thirst/fasting period lasting over 16 h) a third 5-minute-saliva-sample was obtained from the volunteers.
The results suggest that concentrations of epidermal growth factor in saliva increase after longer thirst/ fasting periods and descend to approximately half their original values after water Substitution (tab. 2). The calculated Output of epidermal growth factor and the ratio of epidermal growth factor concentration to the concentration of total protein seem to be nearly constant during thirst and after water Substitution. No significant differences were noticed in epidermal growth factor concentrations in saliva. The group of gastric ulcer patients, however, showed decreased ratios of epidermal growth factor concentratipn to the concentration of total protein (p < 0.01 compared with healthy control) (tab. 3 and fig. 5 ).
Results of gastric juice measurements are demonstrated in table 4 and figure 4. A significant difference in epidermal growth factor concentration and 15-minute-output was seen between gastric ulcer patients and healthy controls (p < 0.01).
The 15-minute Output of epidermal growth factor in patients with gastric ulcer was 5 tirnes lower,.and the epidermal growth factor eoncentration was even 10 times lower than in controls. The values for patients with duodenal ulcer or gastritis did not differ from those of the control group.
The amounts of epidermal growth factor excreted in the urine, based n creatinine, did not differ significantly between the examined collectives.
Tab. 4 Epidermal growth factor concentrations and 15 min Output in gastric juice of control group and patients (mean ± SD).
Epidermal growth factor ** = p < 0.01 compared with healthy controls.
[ 
Discussion
We have develpped an ELISA for the measurernent of epidermal growth factor in body fluids, which has certain advantages, such s shorter incubation time, economical consumption of antibodies (1:150000 and l: 15ΌΟΟ final dilution of monoclonal and polyclonal antibodies, respectively) and high sensitivity, . Epidermal growth factor concentration and ratio of epidermal growth factor concentfation to total protein concentration in saliva. The differences in epidermal growth factor concentration (μ£/1) demonstrated in saliva of all investigated collectives are not statistically significant. Referred to total protein (μg/g protein) it is decreased significantly in gastric ulcer patients. All values are means ± SD ** = p < 0.01 compared with healthy controls the detection limit being 20 ng/1. Changing the incubation time (4 h or overnight) leads to slight shifts of the detection limit. The increased sensitivity, compared with multiple-step-assay-variants using the same antibodies, might be explained by the application of all immunoreactive components in a single incubation phase. This means that equilibrium can be attained in the liquid phase, and is not limited to the cramped spatial conditions on the wall of microtitre plates.
The assay System described above proved to be superior to all other ELISA variants that were tried. A similar assay using rabbit anti-mouse-epidermal growth factor antibodies against human epidermal growth factor (immunological cross-reactivity about 50%) was found to be insufficiently sensitive for our pimposes (detection limit 10 μg/l).
Finally, the polyclonal rabbit anti human epidermal growth factor antibodies (a kind gift from Dr. Gregory, ICI) served its purpose and yielded the expected results under the chosen conditions. The sample di- lution curves show good linearity up to a dilution of l: 2. Decreased measured concentrations of epidermal growth factor in undiluted gastric juice samples are caused by their low pH values. The measurement of epidermal growth factor in saliva samples can be hampered by the fact that the high viscosity can lead to pipetting inaccuracies. Low pH values disturb our assay System due to antibody denaturation, but the immunoreactivity of the epidermal growth factor is unaffected. These problems were avoided by preliminary dilution of all gastric juice and saliva samples with 0.15 mol/1 phosphate buffer, pH 7.4.
In order to investigate the role of epidermal growth factor in gastroduodenal ulcer disease, we analysed gastric juice and saliva from patients with gastroduodenal ulcer and from healthy controls. Although the discussion of ulcerogenesis emphasizes the importance of the balance between protective and destructive factors, the prevailing and exclusive therapeutic strategy is to diminish or neutralize the acid Output in both gastric and duodenal ulcers. These therapeutic concepts acknowledge acid äs the causative agent in ulcerogenesis in accordance with Schwarzes dictum "no acid, no ulcer" (13) . Nevertheless, the protective aspects have also been subject to investigations and especially in the last few years, epidermal growth factor with its numerous effects has received more attention from gastreenterologic researchers.
In cultures of numerous epithelial cells epidermal growth factor increases proliferation and growth and accelerates differentiation (3). Epidermal growth factor accelerates healing of cysteamine-and acid-induced ulcers in rat duodenum (14, 15) . Surgical removal of salivary glands retards healing of acid-induced ulcers in the rat, whereas exogeneous (oral or parenteral) epidermal growth factor application demonstrates a cimetidine-like healing effect or is effective in a protective way without affecting acid secretion (16) . Epidermal growth factor increases the rate of DNA/RNA synthesis and elevates the activity of ornithine decarboxylase which is required for polyamine synthesis (17, 18, 19) .
It was first reported by Ohmura that ulcer patients show decreased amounts of epidermal growth factor in saliva (9) . In this study, it was demonstrated that epidermal growth factor concentrations in patients with gastroduodenal ulcer were lower than in normal subjects, but the results did not differentiate between gastric and duodenal ulcer. We substantiate one of Ohmura's results, i.e. that the highest epidermal growth factor concentrations are present in saliva samples collected in the morning. Our results, however, indicate that the epidermal growth factor concentration in saliva is not subjected to circadian rhythm but is dependent on water balance. Since protein secretion in saliva is adrenergically regulated in contrast to the chölinergically modulated volume secretion, a comparative evalüation of the concentration of epidermal growth factor in saliva alone is difficult due to its dependence on water balance.
We have considered evaluating the total protein concentration and the ratio of epidermal growth factor concentration to the concentration of total protein äs a useful reference parameter. In the thirst/fasting tests, the epidermal growth factor Output and the ratio of epidermal growth factor concentration to the concentration of total protein were correlated with r > 0.85. Applying this ratio to patients and controls* a decrease of the ratio of epidermal growth factor concentration to the concentration of total protein in saliva was nöticed only in gastric ulcer patients, while it remained unchanged in all other collectives.
The concentrations of epidermal growth factor in gastric juice detected by pur ässay systeih are in agreem ent with data reported by other authors (20) . Since there is a considerable intra-and inter-individual fliic* tuation in the secretion rate of gastric juice, we determined epidermal growth factor concentrations and the total volume Output of gastric juice. Decreased epidermal growth factor concentrations and decreased epidermal growth factor Outputs iri gastric juice of patients with gastric ulcer are further indications of the involvement of epidermal growth factor in gastric ulcer disease. Whether the decrease of epidermal growth factor is the cause or the f esült of gastric ulcer disease remains part of the tantalizing etiologic puzzle requiring further investigation.
To our knowledge, this is the first confirmation that the amount of epidermal growth factor in gastrie juice is decreased in gastric ulcer disease. The fact, that epidermal growth factor gastric juice concentrations in patients with duodenal ulcer are within our reference ränge, however, should not lead to the assumption that epidermal growth factor is not involved in duodenal ulcer disease. Üsing the working hypothesis that the decrease öf epidermal growth factor in gastric juice is connected with or leads to uleer disease, it would seem to be useful to investigate epidermal growth factor under the inflüence of anti ulcer drugs such äs äiitisecretagoga or prostaglandin analogues.
